Covenant Partners’s Novartis NVS Stock Holding History

Covenant Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,542	Closed	-$1.04M	–	88
2025 Q4	$1.04M	Hold	7,542	–	–	0.3%	35
2025 Q3	$967K	Hold	7,542	–	–	0.27%	40
2025 Q2	$913K	Hold	7,542	–	–	0.27%	41
2025 Q1	$841K	Hold	7,542	–	–	0.27%	43
2024 Q4	$734K	Sell	7,542 -66	-0.9%	-$7.04K	0.23%	51
2024 Q3	$875K	Buy	7,608 +66	+0.9%	+$7.49K	0.25%	57
2024 Q2	$803K	Hold	7,542	–	–	0.24%	59
2024 Q1	$730K	Sell	7,542 -307	-4%	-$31.5K	0.21%	66
2023 Q4	$793K	Sell	7,849 -90	-1%	-$8.69K	0.25%	61
2023 Q3	$809K	Sell	7,939 -36	-0.5%	-$3.65K	0.29%	53
2023 Q2	$805K	Buy	7,975 +126	+2%	+$12.6K	0.29%	53
2023 Q1	$722K	Sell	7,849 -801	-9%	-$70K	0.28%	57
2022 Q4	$785K	Sell	8,650 -1,809	-17%	-$152K	0.32%	49
2022 Q3	$795K	Hold	10,459	–	–	0.39%	45
2022 Q2	$884K	Sell	10,459 -3,102	-23%	-$272K	0.41%	44
2022 Q1	$1.19M	Buy	13,561 +2,455	+22%	+$213K	0.47%	31
2021 Q4	$971K	Sell	11,106 -3,709	-25%	-$308K	0.36%	56
2021 Q3	$1.21M	Buy	14,815 +3,709	+33%	+$334K	0.48%	40
2021 Q2	$1.01M	Sell	11,106 -3,282	-23%	-$292K	0.38%	50
2021 Q1	$1.23M	Sell	14,388 -4,669	-25%	-$419K	0.49%	33
2020 Q4	$1.8M	Buy	19,057 +9,055	+91%	+$791K	0.76%	20
2020 Q3	$870K	Buy	10,002 +918	+10%	+$79.5K	0.42%	51
2020 Q2	$793K	Sell	9,084 -1,497	-14%	-$129K	0.37%	60
2020 Q1	$872K	Buy	10,581 +3,870	+58%	+$345K	0.47%	41
2019 Q4	$635K	Sell	6,711 -5,256	-44%	-$472K	0.3%	80
2019 Q3	$1.04M	Buy	11,967 +5,256	+78%	+$472K	0.55%	37
2019 Q2	$613K	Sell	6,711 -2,120	-24%	-$179K	0.33%	78
2019 Q1	$761K	Buy	8,831 +2,054	+30%	+$165K	0.42%	48
2018 Q4	$521K	Buy	+6,777	New	+$528K	0.25%	30

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Covenant Partners's NVS Position: Q1 2026 in Review

Covenant Partners sold out of Novartis (NVS) in Q1 2026, closing a stake of 7,542 shares — an estimated $1.04M sold.

Covenant Partners first reported a position in NVS in Q4 2018 and held it in 29 quarters. The position peaked at $1.8M in Q4 2020. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Covenant Partners reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
Covenant Partners sold 7,542 Novartis shares in Q1 2026, an estimated $1.04M.
Covenant Partners first reported a position in Novartis in Q4 2018 and held it in 29 quarters.
Covenant Partners's Novartis position peaked at $1.8M in Q4 2020.
1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Covenant Partners's 13F filing for Q1 2026.